
Research and development of gene therapy medicines for the treatment of rare diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
AstraZeneca
B
Research and development of pharmaceuticals and biotechnologies for various diseases, including cardiovascular, renal, and metabolic diseases.
AstraZeneca
B
Research, development, production, and marketing of prescription medicines in five therapeutic areas: cardiovascular, renal & metabolism, oncology, respiratory & immunology, rare diseases, and vaccines and immune therapies.
Initiatives identified among leaders
Mesure et publication annuelle des émissions GES Scope 3
“AstraZeneca publie des données détaillées sur ses ...” - AstraZenecaDéveloppement de sources d'énergie durable
“Développement de sources d'énergie durable pour ré...” - AstraZenecaPréserver les ressources naturelles
“Orphan Europe préserve les ressources naturelles e...” - Orphan Europe56% of similar organizations communicate on CSR issues
+803 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports